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Abstract
Rationale Atomoxetine is a noradrenaline re-uptake inhibitor
licensed for the treatment of adult and childhood attention
deficit hyperactivity disorder. Although atomoxetine has
established efficacy, the mechanisms which mediate its effects
are not well understood.
Objectives In this study, we investigated the role of cortical
versus sub-cortical noradrenaline by using focal dopamine
beta hydroxylase-saporin-induced lesions, to the prefrontal
cortex (n = 16) or nucleus accumbens shell (n = 18).
Methods Healthy animals were tested by using the forced-
choice serial reaction time task to assess the impact of the
lesion on baseline performance and the response to
atomoxetine and the psychostimulant amphetamine.
Results We observed attenuation in the efficacy of
atomoxetine in animals with lesions to the nucleus accumbens
shell, but not the prefrontal cortex. Amphetamine-induced in-
creases in premature responses were potentiated in animals
with lesions to the prefrontal cortex, but not the nucleus ac-
cumbens shell.
Conclusions These data suggest that noradrenaline in the nu-
cleus accumbens shell plays an important role in the effects of
atomoxetine. Under these conditions, prefrontal cortex nor-
adrenaline did not appear to contribute to atomoxetine’s ef-
fects suggesting a lack of cortical-mediated Btop-down^
modulation. Noradrenaline in the prefrontal cortex appears
to contribute to the modulation of impulsive responding in
amphetamine-treated animals, with a loss of noradrenaline
associated with potentiation of its effects. These data demon-
strate a potential dissociation between cortical and sub-cortical
noradrenergic mechanisms and impulse control in terms of the
actions of atomoxetine and amphetamine.
Keywords Atomoxetine . Amphetamine . Noradrenaline .
Prefrontal cortex . Nucleus accumbens . Impulse control
Introduction
Atomoxetine is a noradrenaline re-uptake inhibitor licensed
for the treatment of adult and childhood attention deficit hy-
peractivity disorder (Christman et al. 2004; Michelson et al.
2002). In both receptor binding studies and in vivo functional
characterization, atomoxetine has been shown to have a rela-
tively selective effect on the noradrenaline transporter (NAT)
versus either the dopamine active transporter (DAT) or sero-
tonin transporter (SERT) (Bymaster et al. 2002; Seneca et al.
2006; Somkuwar et al. 2013), although see Ding et al. (2014)
in relation to SERT occupancy. Although selective for the
NAT, neurochemical studies suggest that atomoxetine also
has effects on cortical dopamine as a result of the relatively
low expression of DAT in the prefrontal cortex (PFC) and the
role of NAT in terminating the effects of dopamine in this
region (Bymaster et al. 2002). As well as effects on the cate-
cholamine transmitters, atomoxetine also has a reasonable af-
finity for the NMDA receptor and may interact with this re-
ceptor at therapeutic doses (Di Miceli and Gronier 2015;
Ludolph et al. 2010). Atomoxetine has also been shown to
increase levels of acetylcholine at doses as low as 0.3 mg/kg
(Tzavara et al. 2006).While the pharmacology of atomoxetine
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and other ADHD treatments is well characterized, the mech-
anisms which underlie their behavioral effects and efficacy are
less well understood.
The link between catecholamines and ADHD is primarily a
result of the drug treatments with limited direct neurobiolog-
ical or genetic evidence for catecholamine dysfunction (Sun
et al. 2014). A more consistent finding is that patients with
ADHD have reduced volume and activity in prefrontal corti-
cal regions which may lead to an imbalance or reduction in
Btop-down^ modulation resulting in impulsivity and inatten-
tion. Some studies have also suggested that psychostimulant
medications improve performance in normal volunteers par-
ticularly when they are fatigued suggesting that the efficacy of
these drugs may not involve a direct interaction with a patho-
logical state (Linssen et al. 2014). Whether or not catechol-
amines play a direct role in ADHD symptomology, under-
standing how treatments such as atomoxetine and
psychostimulants achieve their beneficial effects could help
in the development of improved therapies.
There is detailed literature on the effects of ADHD medi-
cations in humans and at the cellular, circuit, and behavioral
level in animal studies (Berridge et al. 2006; Bymaster et al.
2002; DiMiceli and Gronier 2015; Tucha et al. 2006). Current
theories propose that the stimulant and non-stimulant medica-
tions act through catecholaminergic mechanisms to improve
prefrontal cortical function and both attention and impulse
control (Arnsten 2000; Arnsten and Li 2005; Berridge et al.
2006). Tasks such as the five-choice serial reaction time task
(5-CSRTT) have provided a valuable rodent model where
both visuospatial attention and impulse control can be mea-
sured in rodents. In the 5-CSRTT, atomoxetine has been con-
sistently shown to reduce premature responses (Blondeau and
Dellu-Hagedorn 2007; Fernando et al. 2012; Robinson 2012;
Robinson et al. 2008). Although the PFC has been the main
focus of research, a study by Economidou et al. (2012)
showed that the systemic effects of atomoxetine could be rep-
licated in animals where the drug was directly infused into the
nucleus accumbens shell (NAcSh) but not the core or PFC. In
order to investigate this idea further, we utilized the dopamine
beta hydroxylase (DβH), saporin-conjugated neurotoxin to
induce noradrenergic lesions in the PFC or NAcSh (Milstein
et al. 2007; Wrenn et al. 1996). In order to improve the sensi-
tivity of our assay to detect a reduction in impulsive behavior,
we used a modification of the 5-CSRTT, the forced-choice
SRTT (F-CSRTT) which utilizes only a single response aper-
ture (Murphy et al. 2008). It is hypothesized that removing the
spatial unpredictability of the light cue increases the likelihood
of an impulsive response (Murphy et al. 2008). In our labora-
tory, we observe levels of premature responses between 5 and
10%while this is increased to ∼20% in the forced-choice task
(Robinson 2012). Once animals were trained in the task and
the lesion had been allowed to establish, they were challenged
by using a series of doses of atomoxetine based on previous
studies (Robinson 2012; Robinson et al. 2008). We also
wanted to test the effects of the lesions on the animal’s re-
sponse to amphetamine. This drug has been shown to increase
dopamine release in the nucleus accumbens core resulting in
increased premature responding in the 5-CSRTT (Cole and
Robbins 1989), an effect which is modified in animals with
core versus shell neurotoxic lesions (Murphy et al. 2008). It
was also of interest to see what effect, if any, amphetamine
would have in the animals with PFC NA lesions as this may
lead to an imbalance in the way amphetamine affects the
levels of DA and NA and subsequent activation of post-
synaptic alpha2 adrenoceptors versus D1 receptors.
Methods
Subjects
Subjects were two cohorts of male Lister hooded rats (n = 16
and n = 18) weighing approximately 250 g at the start of
training (Harlan, UK). Rats were housed in groups of four
with standard environmental enrichment (bedding, cardboard
tubes) under temperature-controlled conditions and 12:12-h
reverse light-dark cycle (lights off at 0700 h). Rats were food
restricted to approximately 90 % of their free feeding weight
(∼18 g/day laboratory chow, Purina, UK), with water provided
ad libitum. Procedures were conducted in accordance with the
requirements of the UK Animals (Scientific Procedures) Act
1986 and approved by the University of Bristol Animal
Welfare and Ethical Review Board. Behavioral testing was
carried out between 8 a.m. and 5 p.m. during the animals’
active phase.
Forced-choice serial reaction time task training
Testing was carried out by using rat five-hole operant boxes
(Med Associates, USA), controlled by KLimbic Software
(Conclusive Solutions Ltd., UK). Subjects were trained to
nose poke for a food reward (45 mg Noyes Precision Pellet,
Sandown Scientific, UK) in response to a brief visual stimu-
lus. Each trial was initiated by a nose poke in the magazine
followed by a 5-s inter-trial interval (ITI). The light stimulus
was then presented in the central aperture (0.5 s) followed a
limited hold period (5 s). Only correct responses (response
within the limited hold) were rewarded. In contrast to the 5-
CSRTT, incorrect trials are not recorded in the F-CSRTT as
only the central aperture is used, for task schematic see Fig. 1.
Animals performed 100 trials per session (30-min duration),
with the house light illuminated. Omissions (failure to respond
within the limited hold period) and premature responses (re-
sponse made during the ITI) were punished with a 5-s time-
out and the house light switched off. Omissions are thought to
be indicative of sensory, motor, or motivational factors as
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opposed to attentional accuracy (Robbins 2002). Premature
responding provides a measure of response inhibition, where-
as correct response latency (time from stimulus onset to a
correct response) and magazine latency (time from a correct
response to the reward collection) provide indices of motiva-
tional, sedative, or motor effects. This task differs to the 5-
CSRTT in that animals are not required to attend to multiple
locations as only one aperture is used (Dalley et al. 2004;
Robbins 2002) causing more premature responses and greater
sensitivity for detecting drug-induced reductions in impulsive
responding (Murphy et al. 2008). Animals trained in the 5-
CSRTT in our laboratory typically perform at a level of pre-
mature responses ∼5–10 % of the total trials performed (Benn
and Robinson 2014; Robinson 2012), as opposed to ∼20% for
vehicle conditions in this study. Animals were trained accord-
ing to a graduated protocol as described previously for the 5-
CSRTT (Bari et al. 2008), until they had reached criterion
(>80 correct trials, 0.5-s stimulus duration, 5-s ITI). No sig-
nificant difference between three consecutive sessions was
used to indicate stable baseline performance across task pa-
rameters (% correct, % omissions, % premature responses,
correct and collection latencies). Baseline performance was
analyzed preoperatively and postoperatively and before each
dose response experiment.
Surgical procedure
Following training, animals were assigned to surgical groups
(lesion or vehicle) matched on baseline performance. Surgery
was performed under aseptic conditions. Animals received
bilateral lesions to the PFC (n = 16) or NAcSh (n = 18) by
using stereotaxic injections of the immunotoxin anti-DβH-
saporin (Advanced Targeting Systems, San Diego, USA) to
selectively target noradrenergic afferent fibers (Milstein et al.
2007). Animals were anesthetized with inhaled isoflurane,
placed in a stereotaxic frame (David Kopf Instruments, CA,
USA), and fitted with a nose cone for continuous delivery of
anesthetic. The skull was exposed and intraepicaine (2 %,
Dechra Ltd., Staffordshire, UK) administered locally for post-
operative analgesia. Two burr holes were drilled through the
skull, and the immunotoxin or vehicle administered via a 22-
gauge Hamilton syringe. The concentration of the
immunotoxin for the PFC lesion was 0.04 μg/μL
(dose = 0.02 μg in 0.5 μL per injection) (Milstein et al.
2007) and 0.02 μg/μL (dose = 0.004 μg in 0.2 μL per injec-
tion) for NAcSh lesions. Two injection sites per hemisphere
were used to induce fiber loss across the extent of the PFC and
shell sub-region. Sham-lesioned (sham) rats received vehicle
injections of sterile PBS, pH 7.4. Stereotaxic coordinates used
were (relative to bregma) as follows: PFC anteroposterior
+2.7 and +3.4 mm, lateromedial ±0.6 mm, dorsoventral
−3.6 mm and NAcSh anteroposterior +1.8 and +1.0 mm,
lateromedial ±0.8 mm, dorsoventral −7.8 mm (Paxinos and
Watson 2007). Following surgery, animals were housed in
pairs and given 5–7-day recovery with free access to food
and water. Animals were re-baselined for 10 sessions with
stability confirmed by analysis of the last three baseline ses-
sions (Supplementary Table S1).
Task manipulations
Task manipulations (experiment 1), variable inter-trial
interval (VITI) and noise distractor, were used to in-
crease the demands of the task and assess whether the
lesions had any effects on animals’ ability to respond to
these different conditions. Previous studies by Milstein
et al. (2007) used a similar approach and found effects
for VITI but not for other conditions. Animals per-
formed two consecutive days of baseline (5-s ITI) be-
fore each task manipulation. Each manipulation was
used once to reduce habituation to the altered contin-
gency. The VITI consisted of a 3, 4, 5, or 6-s ITI. Each
ITI was represented equally throughout the session and
presented randomly. The noise distractor consisted of a
single burst of white noise (100 ms, 60 dB intensity)
presented randomly during a 5-s ITI. Task manipula-
tions were performed with the experimenter blind to
the lesion status of the animal.
Drugs
Atomoxetine hydrochloride (Tocris Bioscience, UK) and am-
phetamine (Sigma-Aldrich, UK) were dissolved in 0.9 % sa-
line and administered by intraperitoneal injection in a final
volume of 1 ml/kg; all drugs were prepared fresh each day.
Drug doses used were based on previous studies by using
similar behavioral tasks (Murphy et al. 2008; Robinson
2012; Robinson et al. 2008).
Fig. 1 F-CSRTT trial sequence. Schematic illustrating the sequence of
events for correct, omission, and premature trial types in the F-CSRTT,
adapted from Bari et al. (2008)
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Testing procedure
Animals received drug doses according to a fully randomized
Latin-square design. Each drug day was preceded by a drug-
free baseline test session, with each dose separated by a wash-
out day (no testing or drugs). Atomoxetine dose response
(experiment 2) was performed in the PFC group by using
doses 0.3, 1.0, and 3.0 mg/kg (t = −40 min). As atomoxetine
showed efficacy in this group at 0.3 mg/kg, the subsequent
study in the NAcSh lesion group used a lower starting dose of
0.1, with 0.3, 1.0 mg/kg. For the amphetamine dose response
(experiment 3), both cohorts received the same two doses (0.3,
1.0 mg/kg, i.p. t = −15 min). During amphetamine treatment,
one animal from each cohort was removed from the final
analysis due to a dosing error. Testing was performed with
the experimenter blind to drug treatment and lesion status.
DβH immunohistochemistry and image analysis
Lesion status was confirmed by DβH immunohistochemistry,
following the completion of the behavioral experiments.
Animals were anesthetized with sodium pentobarbitone and
perfused with PBS followed by 4 % paraformaldehyde (0.1 M
PB). The brains were removed, post-fixed in 4 % paraformal-
dehyde, and left to sink in 30% sucrose solution. Brain sections
(40 μm) were cut and stored in cryoprotectant (30 % sucrose,
30 % ethylene glycol, 0.1 M PB) at −20 °C until stained.
All brains were stained at the same time to minimize back-
ground variability across the groups. Incubations were per-
formed at room temperature; each staining step was preceded
by washes in 0.1 M PBS with 0.2 % Triton X-100 (PBS-T),
unless otherwise stated. The staining procedure was as fol-
lows: 3 % hydrogen peroxide (10 min), blocking solution
(3 % horse serum, 2 % bovine serum albumin, PBS-T,
30 min), DβH antibody solution (Merck Millipore, USA,
MAB308, clone 4F10.2, 1:10,000, overnight), biotinylated
horse anti-mouse IgG (Vector Labs, USA, 1:1000, 2–3 h),
ExtrAvidin® solution (Sigma, UK, 1:1000, 2–3 h), and 3,3′-
diaminobenzidine (DAB) solution (Vector Labs, USA, 1–
2 min). Sections were mounted onto slides and cover slipped
by using DPX. A negative control consisted of sections
stained as above with the exclusion of the primary antibody.
Images were acquired by using a Leica DM IRBE inverted
microscope attached to a cooled Hamamatsu CCD camera
(Wolfson Bioimaging Facility, University of Bristol), with
Volocity acquisition software (Improvision, PerkinElmer,
USA). The area of DβH immunoreactivity, indicative of nor-
adrenergic fibers, was measured by using ImageJ software
(NIH) using the BAnalyze Particles^ function. TIFF images
(1024 × 1024 pixels, 8 bits, ×20 magnification) were convert-
ed to binary counting masks after thresholding. Thresholding
was based on the contrast in pixel intensity between specific
staining and background and was consistent across brain
regions. Threshold levels were checked by eye to ensure that
fiber staining corresponded to the pixels selected by ImageJ
(Lorentz et al. 2010; Matragrano et al. 2013). For each image,
the area occupied by pixels with an intensity value above the
background level was converted to mm2 and averaged across
the group. Averaged values were used for brain regions where
multiple stereotaxic levels had been analyzed (Supplementary
Table S2). The experimenter was blind to the lesion status of
the animal.
Statistical analysis
All analyses were conducted by using SPSS for Windows
(version 21, Chicago, USA). Sample size was based on previ-
ous studies by using similar tasks although the effect size for
these novel experiments could not be reliably estimated. Given
the subsequent results observed, the sample size for this type
of interaction study may have been low and this should be
considered for future experiments by using a similar approach.
F-CSRTT performance measures recorded were % correct
(correct responses divided by total number of correct and
omissions), % omissions (omissions divided by total number
of correct and omissions), % premature responses (premature
responses divided by the total number of correct and omis-
sions), correct latency (s), and collection latency (s). Dose
response data for each drug were analyzed by using separate
repeated-measures analysis of variance (RM-ANOVA), with
dose as a within-subject factor and group (lesion or sham) as a
between-subject factor. DβH immunostaining was analyzed
by using RM-ANOVA with region as a within-subject factor
and group as the between-subject factor. Reaction time
data (correct latency) were tested for normality by using
Kolmogorov-Smirnov test; no violations of normality were
found (p > 0.05). Degrees of freedom were adjusted to more
conservative values by using the Huynh-Feldt epsilon for in-
stances of sphericity violation according to Mauchly’s test of
sphericity. Epsilon values (ɛ) are stated where the degrees of
freedom have been corrected. Significant main effects were
further analyzed by post hoc comparisons between vehicle
and drug doses by using least significant difference. The effect
of task manipulations and preoperative/postoperative baseline
performance were analyzed by using unpaired t tests between
sham and lesion groups. Alpha level was set at 0.05, and
graphs were plotted by using Prism 5.0 (GraphPad, USA).
Results
Quantification of DβH noradrenergic fibers
DβH-saporin infusions in the PFC resulted in a noradrenergic
lesion incorporating the cingulate, prelimbic, and infralimbic
cortices (Fig. 2, Table S2, region × group F(26, 364) = 6.55,
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p < 0.001, group F(1, 14) = 25.50, p < 0.001). NA fiber loss
extended into the adjacent orbital cortex, as well as the motor
cortex and perirhinal cortex regions (Fig. 2, Table S2). A re-
duction in DβH immunoreactivity was also observed in more
caudal regions, namely the caudate putamen and NAcSh
(−60 % p = 0.003 and −47 % p = 0.002, respectively).
Animals that had NAcSh DβH-saporin infusions were found
to have selective lesions localized to the shell sub-region only
(Fig. 2, Table S2; region × group F(26, 416) = 3.67, p < 0.001,
group F(1, 16) = 0.05, p = 0.828).
Pretesting baselines
No significant difference was observed across the last three
consecutive baseline sessions pre or post surgery (Table S1).
There were no differences between sham and lesion animals
across performance variables for either PFC or NAcSh cohorts
(Table S1) confirming that groups were matched prior to sur-
gery, and lesions had no effect on baseline performance.
Experiment 1: effects of task manipulations in animals
with PFC or NAcSh noradrenergic lesions
Task performance under a VITI or noise distractor did not
significantly differ between lesion and sham animals for either
the PFC group (Table 1; VITI: all variables t < 1.47, p > 0.172,
noise: all variables t < 1.49, p > 0.159) or NAcSh group
(Table 1; VITI: all variables t < 0.92, p > 0.372, noise: all
variables t < 1.25, p > 0.229, supplementary statistics
Table S3).
Fig. 2 DβH immunostaining and
lesion assessment. Representative
images from the PFC (a) and
NAcSh (b) showing reduced
DβH fiber staining following
DβH saporin lesions versus sham
controls. Images shown are from
the PL and NAcSh, scale
bar = 50 μm; black square
indicates approximate location on
brain atlas. Lesion assessment
summary (c) expressed as the
percentage of DβH
immunostaining compared to
sham controls, see Table S2 for
full list of brain regions analyzed.
PFC (sham n = 8, lesion n = 8)
and NAcSh (sham n = 9, lesion
n = 9), *p < 0.05 sham versus
lesion, within subject. CC corpus
callosum, Cg1 cingulate cortex 1,
Cg2 cingulate cortex 2, CPu
caudate putamen, DβH dopamine
beta hydroxylase, DLO
dorsolateral orbital cortex, IL
infralimbic, LO lateral orbital
cortex, LV lateral ventricle, M1
motor cortex, M2 motor cortex,
MO medial orbital cortex, NAcC
nucleus accumbens core, NAcSh
nucleus accumbens shell, PL
prelimbic, PRh perirhinal cortex,
VO ventral orbital cortex
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Experiment 2: effects of atomoxetine treatment in PFC
versus NAcSh lesion animals
PFC lesions Atomoxetine treatment reduced premature re-
sponses at all doses tested for sham and lesion animals
(Fig. 3a; F(3.0, 42.0) = 29.65, p < 0.001). Correct responses were
reduced (Fig. 3a; F(2.2, 30.9) = 9.80, p < 0.001, ɛ = 0.74) with an
increase in omissions (F(2.2, 30.9) = 9.80, p < 0.001, ɛ = 0.74) at
the highest dose tested in sham (3.0 mg/kg, p = 0.007) and
lesion animals (3.0 mg/kg, p = 0.013). A significant effect of
dose on correct latency and collection latencywas also observed
(Table 2; F(3.0, 42.0) = 27.41, p < 0.001 and F(3.0, 42.0) = 16.85,
p < 0.001, respectively), with increased correct latency in sham
animals (1.0 mg/kg p = 0.002, 3.0 mg/kg p < 0.001) and across
all doses in lesion animals (0.3 mg/kg p = 0.027, 1.0 mg/kg
p = 0.008, 3.0 mg/kg p < 0.001). Collection latency was also
increased in sham (Table 2; 0.3 mg/kg p = 0.024, 1.0 mg/kg
p = 0.003, 3.0 mg/kg p = 0.001) and lesion animals (1.0 mg/kg
p = 0.029, 3.0 mg/kg p = 0.002). No group effect or dose ×
group interaction were found for any performance variables
Table 1 Task manipulations
Task manipulation Group Correct (%) Omission (%) Premature (%) Correct latency (s) Collection latency (s)
VITI PFC sham 89.1 ± 1.6 10.9 ± 1.6 30.6 ± 4.8 1.58 ± 0.13 1.48 ± 0.11
PFC lesion 90.8 ± 1.1 9.2 ± 1.1 22.7 ± 2.5 1.74 ± 0.07 1.36 ± 0.09
NAcSh sham 92.6 ± 1.5 7.5 ± 1.5 45.9 ± 9.7 1.08 ± 0.11 1.58 ± 0.08
NAcSh lesion 93.6 ± 1.5 6.4 ± 1.5 39.3 ± 3.9 1.07 ± 0.07 1.49 ± 0.06
Noise PFC sham 88.6 ± 5.6 11.4 ± 5.6 25.2 ± 5.1 0.92 ± 0.08 1.56 ± 0.08
PFC lesion 95.6 ± 0.6 4.4 ± 0.6 17.3 ± 1.6 1.07 ± 0.07 1.46 ± 0.10
NAcSh sham 94.0 ± 1.4 6.0 ± 1.4 17.3 ± 3.3 0.94 ± 0.10 1.58 ± 0.08
NAcSh lesion 93.4 ± 1.3 6.6 ± 1.3 24.3 ± 4.5 1.00 ± 0.07 1.49 ± 0.07
Performance in the F-CSRTTunder VITI and noise distractor manipulations in animals with PFC or NAcSh noradrenergic lesions. Results are shown for
the total population, mean ± SEM, PFC n = 16, NAcSh n = 18, animals per group
Fig. 3 Atomoxetine dose
response. The effects of
atomoxetine (0.0–3.0 mg/kg) on
F-CSRTT performance in animals
with PFC (a) or NAcSh (b)
noradrenergic lesions. Results are
shown for the total population,
mean ± SEM, n = 16 (PFC
lesions) and n = 18 (NAcSh
lesions) animals per group.
*p < 0.05, **p < 0.01,
***p < 0.001, versus vehicle
(within subject)
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(Fig. 3a, Table 2; F(1.0, 14.0) < 1.12, p > 0.307, and F(3.0,
42.0) < 0.79, p > 0.454, supplementary statistics Table S4).
NAcSh lesions Atomoxetine treatment caused a reduction in
premature responses at the highest dose in sham (Fig. 3b;F(2.6,
41.9) = 5.73, p = 0.003, ɛ = 0.87, 1.0 mg/kg p = 0.001) but not
lesion animals (0.1 mg/kg p = 0.456, 0.3 mg/kg p = 0.557,
1.0 mg/kg p = 0.118). No group effect (F(1.0, 16.0) = 3.90,
p = 0.067) or dose × group interaction (F(2.6, 41.9) = 0.93,
p = 0.425, ɛ = 0.87) were found for premature responses.
Correct responses were reduced, and omissions increased in
sham animals at the highest dose (Fig. 3b; F(2.2, 34.6) = 4.00,
p = 0.025, ɛ = 0.72, 1.0 mg/kg p = 0.043); however, no effect
was found in lesion animals (0.1 mg/kg p = 0.851, 0.3 mg/kg
p = 0.214, 1.0 mg/kg p = 0.500). Atomoxetine treatment also
increased correct latency in sham animals only (Table 2; cor-
rect latency F(3.0, 48.0) = 10.30, p < 0.001, 0.3 mg/kg p = 0.016,
1.0 mg/kg p = 0.002) with collection latency increased across
both groups at the highest dose (Table 2; F(3.0, 48.0) = 13.41,
p < 0.001, 1.0 mg/kg p < 0.001). No group effect or dose ×
group interaction were found for any performance variables
(Fig. 3b, Table 2; F < 1.74, p > 0.104, and F < 2.98, p > 0.104,
supplementary statistics Table S4).
Experiment 3: effects of amphetamine treatment in PFC
versus NAcSh lesion animals
One animal from the PFC and NAcSh groups was removed
from the final analysis for amphetamine due to a dosing error.
PFC lesions Amphetamine treatment increased premature
responding in a dose-dependent manner in sham animals
(Fig. 4a; F(2.0, 26.0) = 47.26, p < 0.001, 1.0 mg/kg p = 0.027,
0.3 mg/kg p < 0.001) and at the highest dose in lesion animals
(0.3 mg/kg p < 0.001). The effect was potentiated in lesion
animals compared to sham animals (Fig. 4a; 1.0 mg/kg
Table 2 F-CSRTT latency data
Treatment Group Dose (mg/kg) Correct latency (s) Collection latency (s)
Atomoxetine PFC sham 0.0 0.83 ± 0.07 1.56 ± 0.10
0.3 1.20 ± 0.24 1.71 ± 0.13*
1.0 1.64 ± 0.27** 1.93 ± 0.19**
3.0 2.34 ± 0.41*** 2.00 ± 0.14**
PFC lesion 0.0 0.92 ± 0.09 1.44 ± 0.06
0.3 1.37 ± 0.24* 1.54 ± 0.09
1.0 1.57 ± 0.15** 1.69 ± 0.13*
3.0 2.43 ± 0.21*** 1.82 ± 0.14**
NAcSh sham 0.0 0.86 ± 0.09 1.57 ± 0.08
0.1 0.95 ± 0.10 1.58 ± 0.07
0.3 1.14 ± 0.12* 1.66 ± 0.10
1.0 1.31 ± 0.14** 1.95 ± 0.14***
NAcSh lesion 0.0 0.78 ± 0.09 1.47 ± 0.05
0.1 0.75 ± 0.05 1.56 ± 0.06
0.3 0.89 ± 0.08 1.53 ± 0.06
1.0 1.01 ± 0.13 1.74 ± 0.08**
Amphetamine PFC sham 0.0 0.91 ± 0.07 1.57 ± 0.10
0.3 0.72 ± 0.10 1.50 ± 0.07
1.0 1.25 ± 0.16* 1.58 ± 0.20
PFC lesion 0.0 0.99 ± 0.11 1.43 ± 0.06
0.3 0.82 ± 0.11 1.35 ± 0.05
1.0 1.16 ± 0.10 1.51 ± 0.22
NAcSh sham 0.0 0.93 ± 0.10 1.56 ± 0.06
0.3 0.80 ± 0.12 1.45 ± 0.10
1.0 0.89 ± 0.13 1.43 ± 0.10
NAcSh lesion 0.0 0.89 ± 0.11 1.52 ± 0.08
0.3 0.71 ± 0.05 1.33 ± 0.06**
1.0 1.24 ± 0.17 1.37 ± 0.04*
The effects of atomoxetine (0.0–3.0 mg/kg) and amphetamine (0.0–1.0 mg/kg) on latency in animals with PFC or
NAcSh noradrenergic lesions. Results are shown for the total population, mean ± SEM, PFC n = 16 (amphetamine
n = 15), NAcSh n = 18 (amphetamine n = 17). *p < 0.05, **p < 0.01, ***p < 0.001, versus vehicle (within subject)
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p = 0.010) with a dose × group interaction (F(2.0, 26.0) = 5.64,
p = 0.009) but not a group effect found (F(1.0, 13.0) = 3.14,
p = 0.100). In sham and PFC lesion animals, amphetamine
reduced correct responses at the highest dose (Fig. 4a; dose
F(1.5, 19.4) = 22.42, p < 0.001, ε = 0.75, 0.3 mg/kg p = 0.001)
and increased omissions (dose F(1.5, 19.4) = 22.42, p < 0.001,
ε = 0.75, 0.3 mg/kg p = 0.001). Correct latency was also
affected by amphetamine treatment (Table 2; dose F(2.0,
26.0) = 14.87, p < 0.001), with an increase at the highest dose
in sham animals (1.0 mg/kg p = 0.011) but no effects observed
in lesion animals (0.3 mg/kg p = 0.109, 1.0 mg/kg p = 0.159).
Collection latency was unaffected by amphetamine treatment
(Table 2; doseF(1.3, 17.4) = 0.51, p = 0.538, ε = 0.67). No group
effect or dose × group interaction were found for any other
performance variables (Fig. 4a; Table 2; F < 3.14, p > 0.10,
and F < 0.95, p > 0.378, supplementary statistics Table S4).
NAcSh lesions Amphetamine treatment affected premature
responses (Fig. 4b; dose F(1.6, 24.4) = 14.43, p < 0.001,
ε = 0.81), with increases observed at 1.0 mg/kg in sham ani-
mals (p = 0.001, 0.3 mg/kg p = 0.062) and at all doses in lesion
animals (0.3 mg/kg p = 0.006, 1.0 mg/kg p < 0.001). The
highest dose also reduced correct responses (Fig. 4b; dose
F(1.3, 19.0) = 18.58, p < 0.001, ε = 0.63) and increased
omissions (F(1.3, 19.0) = 18.58, p < 0.001) although these ef-
fects were only significant for the lesion animals at 1.0 mg/kg
(p = 0.001), but not sham animals (p = 0.079). Collection
latency was reduced in lesion animals at both doses
(Table 2; dose F(2.0, 30.0) = 6.89, p = 0.003, 0.3 mg/kg
p = 0.009, 1.0 mg/kg p = 0.021) but not sham animals
(0.3 mg/kg p = 0.161, 1.0 mg/kg p = 0.121). A main effect
of DOSE was also observed for correct latency (Table 2; F(1.6,
24.7) = 4.85, p = 0.022); however, post hoc tests revealed no
specific effects for sham or lesion animals at any doses
(p > 0.106). No group effect or dose × group interaction were
found for any performance variables (Fig. 4b, Table 2;
F < 1.36, p > 0.221, and F < 3.23, p > 0.18, supplementary
statistics Table S4).
Discussion
These studies support the hypothesis that an important loci for
the effects of atomoxetine on impulse control in the rat is the
NAcSh and involves noradrenaline. Lesions to the NAcSh
attenuated not only atomoxetine’s effects on premature re-
sponses but also its effects on other task variables suggesting
that these may all also be linked to a noradrenergic
Fig. 4 Amphetamine dose
response. The effects of
amphetamine (0.0–1.0 mg/kg) on
F-CSRTT performance in animals
with PFC (a) or NAcSh (b)
noradrenergic lesions. Results are
shown for the total population,
mean ± SEM, n = 15 (PFC
lesions) and n = 17 (NAcSh
lesions) animals per group.
*p < 0.05, **p < 0.01,
***p < 0.001, versus vehicle
(within subject); #p < 0.05 versus
sham (between subject)
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mechanism. Although noradrenaline in the PFC did not ap-
pear to contribute to the efficacy of atomoxetine, the effects of
amphetamine were potentiated in animals with lesions sug-
gesting that PFC noradrenaline provides some degree of mod-
ulatory control under this condition. In removing the norad-
renergic input to the PFC, we may have created an imbalance
in noradrenergic versus dopaminergic modulation meaning
that the effects of amphetamine were potentiated (Arnsten
2011). Unlike previous studies using the 5-CSRTT (Milstein
et al. 2007), we did not observe any differences in animal
performance under baseline conditions or when challenged
by using a VITI or noise distractor. The following discussion
considers the main findings and their implications for the role
of noradrenaline in impulse control and atomoxetine’s
efficacy.
Current theories relating to the role of catecholamines in
ADHD have focused on the PFC and the proposal that nor-
adrenaline, via alpha2 adrenoceptors, and dopamine, via D1
receptors, provide modulatory input which regulates neuronal
firing (Arnsten and Dudley 2005). If there is an imbalance in
the input from these transmitters, impairments in attention and
impulse control, as well as working memory deficits, are ob-
served (Arnsten et al. 1988, 1998; Harrison et al. 1997;
Sawaguchi et al. 1988; Sirvio et al. 1994; Steere and
Arnsten 1997). It is also proposed that psychostimulants,
atomoxetine, and alpha2 adrenoceptor agonists such as
guanfacine remediate the imbalance reducing the symptoms
of ADHD (Arnsten and Dudley 2005; Bari et al. 2009;
Berridge et al. 2006; Pattij et al. 2012). With PFC lesions,
we failed to observe any difference in the actions of
atomoxetine with both sham and lesion animals, exhibiting
improved impulse control in a dose-dependent manner similar
to previous studies (Fernando et al. 2012; Navarra et al. 2008;
Robinson 2012). At the higher doses tested (1.0 and
3.0 mg/kg), we also observed more general effects on task
performance with an increase in omissions and decrease in
correct responses. Response latencies were also increased in
both groups. These findings would suggest that atomoxetine
does not act via cortical noradrenaline but, as discussed below,
involves actions within sub-cortical structures. However, de-
spite the widespread lesion which we achieved in the PFC,
this is not a total lesion, and some noradrenaline fibers remain.
The selectivity of the DβH-saporin immunotoxin has been
confirmed previously, with no depletion of dopamine or
monoaminergic neurons that do not express DβH (Milstein
et al. 2007; Pickel et al. 1975; Wrenn et al. 1996). It is there-
fore likely that cortical dopamine, and any effects of
atomoxetine mediated via this transmitter, would have been
preserved. While our lesion of the NAcSh was very selective,
the PFC lesion was more extensive and some fiber loss was
also observed in the NAcSh. The level of loss was ∼47 %,
while the NAcSh only lesions achieved a loss of ∼75 %.
Given the behavioral data we observed, it would appear that
some loss of noradrenaline from the NAcSh can occur without
impact on atomoxetine’s effects but the 75 % loss observed in
the NAcSh lesion rats is associated with an attenuation in
efficacy. However, we cannot preclude the possibility that
concurrent loss of NA from PFC and NAcSh prevented a
PFC-mediated mechanism from being observed.
The results from the NAcSh lesion animals would suggest
that noradrenaline in this region plays an important role in
mediating atomoxetine’s effects on impulsivity. Previous stud-
ies support this as targeted infusions of atomoxetine into the
shell but not the core or PFC have yielded similar findings
(Economidou et al. 2012). Our work refines this further by
showing that the effects are dependent on an intact noradren-
ergic system. The noradrenergic input to the nucleus accum-
bens region and basal ganglia as a whole is limited, and pre-
vious work has largely overlooked this region in terms of
noradrenaline, much more commonly linking it to dopamine.
The NAcSh appears to receive a relatively large noradrenergic
input with our immunohistochemical analysis showing fibers
as well as terminal fields and a density of DβH staining ap-
proximately two thirds of the level in the PFC. In contrast, the
nucleus accumbens core and caudate nucleus have very low
levels (Berridge et al. 1997). The source of noradrenaline to
the NAcSh is still not fully understood, and few studies have
investigated this, but there has been one paper at least which
proposes that the noradrenaline neurons arise in the nucleus
tractus solitaries rather than the locus coeruleus (Delfs et al.
1998). From our data, it appears that noradrenaline in the
NAcSh is exerting some degree of modulatory influence al-
though further studies are needed to elucidate the exact
mechanism.
From our behavioral data, we observed both a reduction in
atomoxetine’s effects on premature responding but also its
more general effects on motivation, suggesting a possible link
between motivation and impulsivity mediated by NAcSh nor-
adrenaline. In general, the nucleus accumbens core and dopa-
mine release within this region have been linked to impulsiv-
ity, particularly in the 5-CSRTT (Besson et al. 2010; Murphy
et al. 2008). The NAcSh region has been less well character-
ized in models of impulsivity but has been studied extensively
in motivation (Pecina et al. 2006; Reynolds and Berridge
2002). Bringing these ideas together with our behavioral data,
we hypothesize that noradrenaline in the NAcSh is acting to
regulate the motivational state and arousal which underlies the
premature response in the F-CSRTT. If this is the case, then
atomoxetine may facilitate this noradrenergic mechanism
resulting in improved control in animals presented with a
cue associated with responding for reward.
The effects of amphetamine were also interesting and re-
vealed a dissociation between the different lesion groups. No
effects were observed in NAcSh-lesioned animals; however,
animals with a PFC noradrenaline lesion exhibited a potenti-
ated response to amphetamine. A link between the nucleus
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accumbens core and shell and impulsive behavior in response
to amphetamine has previously been shown by Murphy et al.
(2008). In this study, NAcSh lesions were associated with an
attenuated response to amphetamine, while lesions to the core
resulted in a potentiated effect on premature responses
(Murphy et al. 2008). However, our data suggest that removal
of only noradrenergic inputs to the NAcSh region does not
have any effects on performance in the F-CSRTT under base-
line conditions or during challenging conditions (amphet-
amine, VITI, noise). In contrast, PFC noradrenaline appears
to contribute in some way to modulating the effects of am-
phetamine, and our data would suggest that this is via an
inhibitory role. The most likely explanation for this is the
hypothesis that both NA and DA act together in the PFC to
regulate behavior. A balance between alpha2 and dopamine
D1 activation helps to optimize PFC neuronal function and
cognition (Arnsten and Dudley 2005). By removing the nor-
adrenergic input to the PFC and administering amphetamine,
the rise in catecholamine transmission in the PFC would be
limited to dopamine and result in excessive activation of D1
receptors. A large body of work has shown that the balance
between DA and NA in the PFC plays a critical role in cog-
nition and the actions of psychostimulants (Arnsten and
Dudley 2005; Berridge and Arnsten 2012; Milstein et al.
2010; Schmeichel and Berridge 2013; Spencer et al. 2015).
The dissociation between the behavioral effects of amphet-
amine and atomoxetine in the different lesion groups may have
relevance to the clinical situation, as responder efficacy has been
linked to the type of ADHD (hyperactive/impulsive, inattentive,
combined) as well as different functional outcomes (Fredriksen
et al. 2013; Newcorn et al. 2008). Our results suggest that am-
phetamine and atomoxetine differentially interact with the NA
system when different regions are impaired, something which
may also be relevant to the clinical presentation of ADHD.
Although, it should be noted that this work was done in normal
rats by using a dose range consistent with the recommended
daily dose prescribed in patients (Childress and Berry 2012;
Sharma and Couture 2014). Further studies to investigate these
findings and understand more about the underlying neurobiolo-
gy may help in providing better management of patients with
the most appropriate treatments. Although these data suggests
dissociation between cortical (PFC) versus sub-cortical
(NAcSh) noradrenaline in impulse control, this work does not
preclude other actions of atomoxetine (e.g., increasing cortical
acetylcholine) or provide insight into the attentional effects of
the drug (Tzavara et al. 2006). Several limitations of the study
also need to be taken into consideration.We cannot preclude the
possibility that concurrent damage to sub-cortical structures in
the PFC-lesioned animals may have precluded a specific effect
of atomoxetine in these animals. However, our study assessed
fiber loss across a wider range of brain regions by using a quan-
titative approach, which may have uncovered a greater extent of
fiber loss than previously shown (Milstein et al. 2007).
Our baseline premature responses in the F-CSRTT are
higher than those typically observed in our 5-CSRTT (Benn
and Robinson 2014; Robinson 2012), although the levels ob-
served in this study were much lower than those previously
reported for the F-CSRTT (Murphy et al. 2008). Alternative
methods to increase premature responding could be used in
future studies such as a long inter-trial interval (Economidou
et al. 2012). If baseline premature respondingwere higher, this
might also increase the effect size and help address the issues
seen in this study around power. It may also be necessary to
increase the same size when looking at these interactions be-
tween lesion and drug effects. At the doses tested, no effects of
atomoxetine were observed in NAcSh lesion animals although
we tested a lower dose range in this group to try to maximize
our opportunity for seeing an effect. If we tested higher doses,
we may also see effects in the NAcSh lesion animals arising
either from actions in other brain regions associated with the
effects of the drug on the residual noradrenaline fibers. We
also need to consider the impact of the PFC lesions on shell
NA innervations.
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